64995-73-9

Basic information

• Product Name: 1H-Purine-2,6-dione, 3,7-dihydro-7-methyl-3-(phenylmethyl)-
• CAS NO: 64995-73-9
• Molecular Formula: C13H12N4O2
• Molecular Weight: 256.264
• Mol File: 64995-73-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Purine-2,6-dione, 3,7-dihydro-7-methyl-3-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Purine-2,6-dione, 3,7-dihydro-7-methyl-3-(phenylmethyl)-(64995-73-9)
• EPA Substance Registry System: 1H-Purine-2,6-dione, 3,7-dihydro-7-methyl-3-(phenylmethyl)-(64995-73-9)

Safety Data

• Hazardous Substances Data: 64995-73-9(Hazardous Substances Data)

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 72816-88-7 6-amino-1-benzyl-5-N-methylaminouracil 
• 64995-66-0 4-(N-benzylamino)-1-methyl-1H-imidazole-5-carboxamide 
• 72816-87-6 6-amino-1-benzyl-5-bromo-2,4(1H)-pyrimidinedione 

Downstream Products

• 139927-95-0 3-<(4-methoxymethoxy)-3-nitrobenzyl>-1,7-dimethylxanthine 
• 139927-96-1 3-(4-hydroxy-3-nitrobenzyl)-1,7-dimethylxanthine 
• 611-59-6 paraxanthine 
• 552-62-5 7-methylxanthine 
• 7499-88-9 1,7-Dimethyl-3-benzylxanthine 
• 139928-00-0 3-Benzyl-1-ethyl-7-methyl-3,7-dihydro-purine-2,6-dione 

Relevant articles and documents

Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors

Fragment-based drug design was used to identify Mycobacterium tuberculosis (Mtb) dihydrofolate reductase (DHFR) inhibitors. Screening of ligands against the Mtb DHFR enzyme resulted in the identification of multiple fragment hits with IC50 values in the range of 38–90 μM versus Mtb DHFR and minimum inhibitory concentration (MIC) values in the range of 31.5–125 μg/mL. These fragment scaffolds would be useful for anti-tubercular drug design.

Purines. XLIX. Synthesis and proton nuclear magnetic resonance study of 3,7-dialkylxanthines and 1,3,7-trialkylxanthines

A general synthetic route to 3,7-dialkylxanthines (type 9) from 3,7-dialkyladenines (6) [hence from 3- or 7-alkyladenines (11 or 10)] has been established. The route started with ethoxycarbonylation of 1-alkyl-4-(alkylamino)1H-imidazole-5-carboxamides (7), readily obtainable from 6 by alkaline hydrolysis, and proceeded through cyclization of the resulting carbamates (8) under alkaline conditions. Alkylation of 9 with alkyl halide in N,N-dimethylformamide in the presence of anhydrous K2CO3 extended the above synthetic route to the 1,3,7-trialkylxanthine level (type 14). Hydrogenolytic deb nzylation of 3-benzyl-1,7-dimethylxanthine (16), prepared by following this general synthetic route, furnished paraxanthine (26) in fair yield. Conversion of 26 into 3-(4-hydroxy-3-nitrobenzyl)-1,7-dimethylxanthine (24), isomeric with the bryozoan purine phidolopin (2), was effected through aralkylation with 4-(methoxymethoxy)-3-nitrobenzyl bromide (28) followed by O-deprotection. On the basis of proton nuclear magnetic resonance data for the 3,7-dialkylxanthines (3 and 9b-i) and 1,3,7-trialkylxanthines (5 and 14-22) thus prepared, reliable criteria for distinguishing signals of N-alkyl substituents at various positions are put forward.